Msd K.k.

Fujifilm Corporation

Merck Sharp + Dohme Corp.

Banyu Pharmaceutical Co. Ltd

Hidetomo Furuyama

Toshihiro Sakamoto

Fuyuki Yamamoto

Takashi Yoshizumi

Yasuhiro Goto

Keiji Takahashi

Makoto Bamba

Satoshi Sunami

Daisuke Sasaki

Kenji Niiyama

Nobutaka Fukagawa

Takeshi Sagara

Hiroshi Hirai

Sachie Otsuki

Toshihide Nishibata

Yoshihiro Jimbo

Mark E Layton

Philip E Sanderson

Yu Naito

Jiabing Wang

Yoshio Ogino

Daisuke Nakagawa

Nobuhiko Kawanishi

Takashi Mita

Hiroki Kuwahara

Hideki Kurihara

Yu Onozaki

Takahiro Terao

Takayuki Kato

Masahiko Yamamoto

Satoshi Ueda

Akihiro Hara

Akira Naya

Michael A Rossi

Kevin J Rodzinak

Natsuru Chikushi

Tomoyuki Mashiko

Shinichiro Sekine

Shintaro Tanabe

Mikako Kawamura

Shinsuke Inuki

Kentarou Furuya

Shinichirou Sekine

Provided are a resin composition including a coloring agent represented by Formula 1 and a resin; a liquid composition; a coloring agent compound; and an optical material. In Formula 1, Rand Reach independently represent an alkyl group or an aryl group, R, R, R, and Reach independently represent a hydrogen atom or a substituent, and Rand Rmay be bonded to each other to form a 6-membered ring.

Resin composition, liquid composition, coloring agent compound, and optical material

Provided are a resin composition including a compound represented by Formula (1) and a resin, an optical filter including the resin composition, a liquid crystal display device and a solid-state imaging element including the optical filter, and a compound suitable as a light absorbing component of the resin composition. In Formula (1), Dye represents a colorant structural part obtained by removing n1 hydrogen atoms from a squarylium compound having a specific structure, Qis a structural part including a metallocene structure, and n1 represents an integer of 1 to 6.

Resin composition, optical filter, image display device, solid-state imaging element, and compound

Provided are a wavelength selective absorption filter including a resin and the following dye A and dye D, each of which has a main absorption wavelength band in a different wavelength range, in which an absorbance Ab (λ) at a wavelength λ nm of this wavelength selective absorption filter satisfies a relationship of the Relational Expression (I) 0.05<Ab (450)/Ab (430)<1.00, as well as a polarizing plate and an organic electroluminescent display device or liquid crystal display device including the wavelength selective absorption filter. The dye A is a dye having a main absorption wavelength band in the wavelength selective absorption filter at a wavelength of 400 to 430 nm. The dye D is a dye having a main absorption wavelength band in the wavelength selective absorption filter at a wavelength of 640 to 730 nm.

Wavelength selective absorption filter, organic electroluminescent display device, and liquid crystal display device

Provided are a polarizing plate protective film including a resin and a coloring agent having an absorption maximum wavelength in a range of 560 to 620 nm or 460 to 520 nm in an amount of 0.1 parts by mass or more with respect to 100 parts by mass of the resin, in which a film thickness is 1 to 18 &#x3bc;m, and a moisture content is 0.5% by mass or less, a polarizing plate in which the protective film is used, and a liquid crystal display device in which the polarizing plate is used.

Polarizing plate protective film, polarizing plate, and liquid crystal display device

A compound represented by Formula [1](in the formula, Zrepresents N, CH, or the like; Xrepresents NH or the like; Rrepresents a heteroaryl group or the like; each of R, R, and Rrepresents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and Rrepresents a heteroaryl group or the like) or salt thereof. 

Nitrogen-containing heterocyclic compound or salt thereof

A 1,5-naphthyridine derivative represented by Formula [1] (in which R, R, R, Rand Rrepresent a hydrogen atom, -L-Z (in which Z represents a non-aromatic heterocyclic group or the like; and L represents a single bond or the like), or the like, Rrepresents -L-Z or the like, Rand Rrepresent a hydrogen atom or the like, and Q represents an oxygen atom or the like), or a salt thereof has an excellent inhibitory activity with respect to the PI3K-AKT pathway and the Ras-Raf-MEK-ERK pathway, and is useful for treatments such as prophylactic treatments and therapeutic treatments of diseases in which the PI3K-AKT pathway and the Ras-Raf-MEK-ERK pathway are involved.

1,5-naphthyridine derivative or salt thereof

The invention relates to compounds of a general formula (I): wherein Aris an optionally-substituted aryl or heteroaromatic group; Ris an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; Ris a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; Ris a hydrogen atom or a lower alkyl group; Ris a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of &#x2014;N(R)R; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

Dihydropyrazolopyrimidinone derivatives

The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.

Inhibitors of AKT activity

The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Aris an optionally substituted aryl or heteroaryl group; Ris a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; Ris an optionally substituted aryl, aralkyl, or heteroaryl group; and Ris a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Wee1 kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy. 

Dihydropyrazolopyrimidinone derivative

The invention relates to a compound of a general formula (I): wherein Aand Aeach mean a nitrogen atom or an optionally-substituted methine group; Ring B means a 5-membered to 7-membered aliphatic ring, or a spiro or bicyclo ring formed from the aliphatic ring and any other 3-membered to 7-membered aliphatic ring; Rmeans a hydrogen atom, or an optionally-substituted C1-C6 alkyl group, or an optionally-substituted aryl, aralkyl or heteroaryl group; Rmeans an optionally-substituted aryl, aralkyl or heteroaryl group; and X means a group of &#x2550;NH or &#x2550;O, etc. Based on its excellent Wee1 kinase-inhibitory effect, the compound of the invention has cell growth-inhibitory effect and has an additive/synergistic effect with any other anticancer agent, and is therefore useful in the field of medicine.

Bicycloaniline derivative

The invention relates to compounds of general formula (I-0): wherein R, R, R, R, R, R, R, R, X, and Y are as defined herein. Compounds of the invention have, based on excellent Wee1 kinase-inhibitory effect, a cell growth-inhibitory effect and an additive/synergistic effect with any other anticancer agent, and are therefore useful in the field of medicine.

Pyridone-substituted-dihydropyrazolopyrimidinone derivative

The compounds of Formula D are of the class of triazolo-pyrido-pyrazines which are inhibitors of AKT useful for the treatment of cancer 

Substituted [1,2,4]triazolo[4',3&#x2032;:1,6]pyrido[2,3-b]pyrazines of the formula D

Substituted pyrazolo[3,4-d]pyrimidinone derivatives

Growing community of inventors

Ashigarakami-gun, Japan

Hidetomo Furuyama